Logo

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Share this
Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Shots:

  • The P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study involves assessing of Takhzyro (300/150 mg- SC) (lanadelumab) vs PBO in 125 patients with HAE attacks for 26 weeks aged 12 years and older
  • The P-III HELP result: reduction in mean monthly attack rate 80.1% ; fewer severe attacks (7.4% vs. 22%); HAE attack-free (48.1% vs 7.3%); attacks requiring acute treatment (74% vs 87%); moderate or severe attacks (70% to 83%)
  • Takhzyro is a mAb produced using Chinese Hamster Ovary (CHO) cells by recombinant DNA technology and decreases plasma kallikrein activity. Takhzyro 300mg has received FDA’s approval as prophylaxis for the prevention of HAE attacks in patients aged 12 years and older

Ref: Takeda | Image:Takeda

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions